Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 27Gastrointestinal 1Classical hematology 1CNS 1

Conditions

Thrombocytopenia 1Cytopenia 1Anemia 1

Interventions

Cyclophosphamide 11fludarabine phosphate 9Whole-Body Irradiation 8Mycophenolic Acid 7Busulfan 6fludarabine 5Tacrolimus 5Peripheral Blood Stem Cell Transplantation 5Melphalan 5Rituximab 4Biopsy 4Azacitidine 4venetoclax 3apixaban 3Cyclosporine 3thymoglobulin 2decitabine and cedazuridine drug combination 2Vorinostat 2Vancomycin 2Tretinoin 2Specimen Handling 2Sirolimus 2Methotrexate 2Lenalidomide 2Injections 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Decitabine 2Cytarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pluvicto × Classical hematology × 90 days × Clear all
NCT07025512 2026-05-08

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Classical hematology

Cytopenia, Anemia, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡